A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION “Permanent Introduction of Premium for New Drug Development Premature”: CSIMC Member Adachi
September 30, 2011
-
BUSINESS MS Pharma Forms Strategic Alliance with Korean Company in Biosimilars
September 30, 2011
-
BUSINESS Takeda President Hasegawa Eyes Joint Research with Chinese Companies
September 29, 2011
-
REGULATORY CSIMC’s Committee to Assess Premium for New Drug Development Based on Results of Market Price Survey
September 29, 2011
-
BUSINESS MTPC to Start PIII Trial for Telaprevir in China Early 2012
September 29, 2011
-
ORGANIZATION JPMA Head Says Industry Will Support Infrastructure Development for Innovative Drug Discovery
September 28, 2011
-
BUSINESS Astellas Pharma Debuts on DJSI Asia Pacific Index
September 28, 2011
-
BUSINESS BMS to File for Apixaban for Stroke Prevention in Japan, US, and Europe Before Year-end
September 27, 2011
-
ORGANIZATION Continuation of Premium for New Drug Development to Depend on Effects on Drug Lag, Drug Development: Mr Shirakawa of Kenporen
September 26, 2011
-
REGULATORY 6 APIs/10 Products Including EpiPen Added to NHI Price List
September 22, 2011
-
BUSINESS Novartis Grows 7% Driven by New Products: President Mitani
September 22, 2011
-
BUSINESS Kaken President Onuma Targets ¥20 Billion in Operating Profits in 2015
September 21, 2011
-
ORGANIZATION FPMAJ Seeks Improved System for Orphan Drug Development, Request to Be Submitted Soon to Health Minister
September 20, 2011
-
REGULATORY HSC Subcommittee Agrees on Need for New System to Promote Access to Unapproved Drugs
September 20, 2011
-
REGULATORY Preparations Underway for MHLW to Set Up Private Third-Party Committee
September 16, 2011
-
REGULATORY Council Recommends 5 Drugs as Appropriate for Application Based on Info. in Public Domain
September 16, 2011
-
BUSINESS Small, Medium-Sized Generic Drug Makers’ Business Improves Amid Uncertainty Over Future
September 15, 2011
-
BUSINESS Supreme Court Rules Against GE Drug Makers, Allows Patent Extension for Eisai’s Aricept
September 15, 2011
-
ACADEMIA NCGM Hospital Removes Actos from List of Recommended Drugs in Diabetes Manual
September 14, 2011
-
ORGANIZATION FPMAJ Announces Its Basic Policy on Providing Info. on Drugs Used Off-label
September 13, 2011
ページ
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…